<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210222050463N12</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-26</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>Effect of melatonin on preventing confusion after orthopedic surgery in elderly diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Prophylactic Melatonin Administration on the Incidence of Postoperative Delirium in Diabetic Geriatric Patients Undergoing Orthopedic Surgery under General Anesthesia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-11-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94305</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: This study is a randomized controlled trial. The unit of randomization is individual patients. Eligible patients will be randomly allocated into two groups (intervention and control) using a simple randomization method with a computer-generated random number table. No stratification is applied in this study. The random sequence was generated by an individual independent of the clinical team and principal investigators using a computer software to minimize selection bias. Allocation concealment will be strictly maintained using coded medication packages (identically appearing packages containing either melatonin or placebo), Blinding description: This study is designed as a double-blind clinical trial. All patients, surgeons, anesthesiologists, nursing staff, and outcome assessors are blinded to the group assignments. To ensure this, the control group receives identically appearing placebo capsules (matching in shape, taste, and odor) at the exact same time points as the intervention group. Furthermore, allocation concealment is strictly maintained using coded medication packages. The randomization process is conducted by an individual independent of the clinical team, ensuring that the investigators and clinical staff remain unaware of the group allocations throughout the study. Outcome assessments will be performed by two independent evaluators who are also blinded to the group allocation.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Postoperative delirium (POD) is an acute and fluctuating disturbance in attention and cognition that occurs within the first 72 hours after surgery. This study specifically investigates its incidence and severity in elderly diabetic patients following orthopedic surgery under general anesthesia. Condition 2: Diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose levels. This study focuses on elderly patients (aged 60 years and older) with a confirmed diagnosis of diabetes who are at a higher risk of developing postoperative delirium.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Receiving oral melatonin capsules (5 mg) at 21:00 the night before surgery, 30 minutes before anesthesia induction, and at 21:00 for three consecutive nights postoperatively, administered with 15 mL of water. Intervention 2: Control group: Receiving identically appearing placebo capsules (matching in shape, taste, and odor) at the exact same time points (21:00 the night before surgery, 30 minutes before anesthesia induction, and 21:00 for three consecutive nights postoperatively), administered with 15 mL of water.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is Due to strict patient confidentiality and privacy regulations, as well as the data ownership policies of the research team and university, there is currently no plan to share individual participant data. The study results will be published in aggregate form in a peer-reviewed journal.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Vahid Saidkhani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golestan Blvd</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6143975617</zip>
        <telephone>+98 916 092 6605</telephone>
        <email>saidkhani-v@ajums.ac.ir</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nooshin Sarvi-Sarmeydani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Paramedicine, Anesthesiology Department, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd., Ahvaz</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6135715794</zip>
        <telephone>+98 61 3333 0011</telephone>
        <email>nooshinsarvi9192@gmail.com</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 60 years or older.
Patients with a confirmed diagnosis of diabetes mellitus.
Candidates for elective orthopedic surgery (total hip replacement, total knee replacement, or fracture repair) under general anesthesia.
Abbreviated Mental Test (AMT) score of 8 or higher.
Willingness to participate and providing written informed consent.</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of using medications with known interactions with melatonin (e.g., warfarin, flumazenil, or immunosuppressive agents).
Known allergy or hypersensitivity to melatonin.
Severe cognitive impairment (AMT score less than 8) or history of severe psychiatric disorders.
Severe hepatic or renal impairment.
Active alcohol or substance abuse.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F05</hc_code>
      <hc_code>E11</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Delirium due to known physiological condition</hc_keyword>
      <hc_keyword>Type 2 diabetes mellitus</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Receiving oral melatonin capsules (5 mg) at 21:00 the night before surgery, 30 minutes before anesthesia induction, and at 21:00 for three consecutive nights postoperatively, administered with 15 mL of water.</i_keyword>
      <i_keyword>Control group: Receiving identically appearing placebo capsules (matching in shape, taste, and odor) at the exact same time points (21:00 the night before surgery, 30 minutes before anesthesia induction, and 21:00 for three consecutive nights postoperatively), administered with 15 mL of water.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Incidence of postoperative delirium (defined as a positive diagnosis based on the Confusion Assessment Method for the Intensive Care Unit criteria). Timepoint: During the first 72 hours postoperatively (assessed twice daily at 8:00 AM and 8:00 PM). Method of measurement: Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) administered by trained evaluators blinded to group allocation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Severity of postoperative delirium. Timepoint: On the days when delirium is diagnosed during the first 72 hours postoperatively. Method of measurement: Memorial Delirium Assessment Scale.</sec_outcome>
      <sec_outcome>Duration of delirium. Timepoint: During the first 72 hours postoperatively (assessed twice daily). Method of measurement: Number of days with at least one positive assessment using the Confusion Assessment Method for the Intensive Care Unit.</sec_outcome>
      <sec_outcome>Length of hospital stay. Timepoint: From the day of surgery until the day of hospital discharge. Method of measurement: Review of patient medical records and hospital admission and discharge dates.</sec_outcome>
      <sec_outcome>Serum melatonin level. Timepoint: Preoperatively, 24 hours postoperatively, and 72 hours postoperatively. Method of measurement: Venous blood sampling and measurement using validated Enzyme-Linked Immunosorbent Assay kits.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Ahvaz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-09</approval_date>
        <contact_name>Ethics committee of Ahvaz Jundishapur University of Medical Sciences</contact_name>
        <contact_address>Vice Chancellery for Research and Technology, 1st Floor, Ahvaz Jundishapur University of Medical Sciences, Golestan Blvd., Ahvaz Ahvaz Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
